NCT Number: NCT00065897
Prenatal Testing: Amniocentesis Versus Transabdominal Chorionic Villus Sampling (TA CVS)
Prenatal diagnosis can provide information to parents about specific fetal disorders. However, invasive prenatal diagnostic procedures are associated with risks to the fetus. This study will compare the safety and effectiveness of two methods of invasive prenatal diagnosis: amniocentesis and transabdominal chorionic villus sampling (TA CVS).
Looking for future studies?
Notify MeKey information
Conditions
Age range
34 year–60 year
Sex eligibility
Female
Study type
Interventional
Phase
Not applicable
About this study
Amniocentesis is generally performed at 105 to 125 days post last menstrual period (LMP) and TA CVS at 63 to 76 days post LMP. This study will compare the safety and accuracy of transabdominal amniocentesis and TA CVS, each performed during the same modified gestational age window of 77 to 104 days post LMP.
Healthy, pregnant women at 77 to 104 days gestation, whose only indication for prenatal diagnosis is advanced maternal age of at least 34 years at enrollment, will be randomized to receive either TA CVS or amniocentesis following a baseline ultrasound. Eligible women who refuse randomization or for whom a procedure cannot be scheduled by 104 days will also be followed. Primary outcomes include fetal loss or preterm delivery before 196 days gestation as well as total fetal loss, amniotic fluid loss, gestational age at delivery, perinatal morbidity, neonatal morbidity, and congenital abnormalities, including limb reduction defects. Success in obtaining a diagnosis from the two procedures will be compared. One ancillary study will evaluate the feasibility and accuracy of fluorescence in situ hybridization (FISH) as a rapid diagnostic method for certain cytogenetic abnormalities; another will collect data on amniotic fluid alphafetoprotein and acetylcholinesterase for the diagnosis of neural tube defects.
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Singleton pregnancy confirmed by baseline ultrasound
- At least 77 days gestation but not more than 104 days gestation confirmed by baseline ultrasound
Exclusion criteria
- Evidence of "vanishing" twin
- Bleeding equivalent to a menstrual period at any time during this pregnancy
- Medical history indicating serious maternal illness or potential teratogenic exposure
- Oligohydramnios
- Known fetal abnormality
- Dating inconsistency: if the estimated gestation is 8 or more days less than estimated by LMP, the patient is excluded unless interval growth by ultrasound confirms the normalcy of the pregnancy
Treatment and study plan
Transabdominal chorionic villus sampling (TA CVS)
ProcedureSponsors and collaborators
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Nih
Registry information
Official study title
Randomized Trial of 11-14 Week Amniocentesis and Transabdominal Chorionic Villus Sampling (TA CVS)
Important dates
- Study start
- 1996
- Study completion
- 2000
- First posted
- Aug 5, 2003
- Registry last updated
- Jun 24, 2005
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
The Effect of Affirmation During Non-Stress Test on Pain, Anxiety, Fear, and Stress
NCT07667920
Anxiety, Anxiety Disorders
Istanbul, Turkey (Türkiye)
View Trial DetailsDexamethasone for Post-operative Pain After Cesarean Delivery Under Neuraxial Anesthesia.
NCT07257406
Cesarean Delivery, Dexamethasone
Montreal, Quebec, Canada
View Trial DetailsMaternal Burnout, Breastfeeding Self-Efficacy and Attachment Level
NCT07112495
Behavior, Behavioral Symptoms
Sakarya, Turkey (Türkiye)
View Trial DetailsVerTouch Device: A Prospective Randomized Controlled Trial
NCT04630171
Neurologic Manifestations, Pain
Chicago, Illinois, United States
View Trial Details